APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba

ABSTRACT Background: There is little information on the association of the APOEe4 allele and AD risk in African populations. In previous analyses from the Indianapolis-Ibadan dementia project, we have reported that APOE ε4 increased the risk for Alzheimer's disease (AD) in African Americans but not in Yoruba. This study represents a replication of this earlier work using enriched cohorts and extending the analysis to include cognitive decline. Methods: In this longitudinal study of two community dwelling cohorts of elderly Yoruba and African Americans, APOE genotyping was conducted from blood samples taken on or before 2001 (1,871 African Americans & 2,200 Yoruba). Mean follow up time was 8.5 years for African Americans and 8.8 years for Yoruba. The effects of heterozygosity or homozygosity of ε4 and of the possession of e4 on time to incident AD and on cognitive decline were determined using Cox's proportional hazards regression and mixed effects models. Results: After adjusting for covariates, one or two copies of the APOE ε4 allele were significant risk factors for incident AD (p < 0.0001) and cognitive decline in the African-American population (p < 0001). In the Yoruba, only homozygosity for APOE ε4 was a significant risk factor for AD (p = 0.0002) but not for cognitive decline (p = 0.2346), however, possession of an e4 allele was significant for both incident AD (p = 0.0489) and cognitive decline (p = 0.0425). Conclusions: In this large longitudinal comparative study, APOE ε4 had a significant, but weaker, effect on incident AD and on cognitive decline in Yoruba than in African Americans. The reasons for these differences remain unclear.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[3]  O. Gureje,et al.  Cholesterol, APOE genotype, and Alzheimer disease , 2006, Neurology.

[4]  O. Gureje,et al.  APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. , 2006, Annals of neurology.

[5]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[6]  D. Knopman,et al.  Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study , 2009, Alzheimer's & Dementia.

[7]  O. Gureje,et al.  Association of apolipoprotein E genotype and Alzheimer disease in African Americans. , 2006, Archives of neurology.

[8]  G. Martin.  APOE alleles and lipophylic pathogens , 1999, Neurobiology of Aging.

[9]  Pierre Joly,et al.  Interval-censored time-to-event and competing risk with death: is the illness-death model more accurate than the Cox model? , 2013, International journal of epidemiology.

[10]  O. Gureje,et al.  Incidence and Risk Factors for Cognitive Impairment No Dementia and Mild Cognitive Impairment in African Americans , 2011, Alzheimer disease and associated disorders.

[11]  K. Hall,et al.  Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites , 2000, International journal of geriatric psychiatry.

[12]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[13]  O. Gureje,et al.  APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians , 2006 .

[14]  Caleb E. Finch,et al.  The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms☆ , 1999, Neurobiology of Aging.

[15]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[16]  O. Gureje,et al.  A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians. , 2008, Ethnicity & disease.

[17]  D. McGee,et al.  Baseline age effect on parameter estimates in Cox models , 2012 .

[18]  T. Gonzalez,et al.  ICD 10 , 2015, Foot & ankle international.

[19]  K. Hall,et al.  The CAMDEX: A Standardized Instrument for the Diagnosis of Mental Disorder in the Elderly: A Replication with a US Sample , 1988, Journal of the American Geriatrics Society.

[20]  C. Finch,et al.  Meat‐Adaptive Genes and the Evolution of Slower Aging in Humans , 2004, The Quarterly Review of Biology.

[21]  O. Gureje,et al.  Apolipoprotein E—associated risk for Alzheimer's disease in the African‐American population is genotype dependent , 1997, Annals of neurology.

[22]  S. Kanba,et al.  Apolipoprotein Genotype for Prediction of Alzheimer's Disease in Older Japanese: The Hisayama Study , 2011, Journal of the American Geriatrics Society.

[23]  A Ogunniyi,et al.  Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. , 2001, JAMA.

[24]  L. Fried,et al.  Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. , 1998, Stroke.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[26]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[27]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[28]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[29]  O. Gureje,et al.  The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures , 2006, International Psychogeriatrics.

[30]  O. Gureje,et al.  Homocysteine levels and dementia risk in Yoruba and African Americans , 2013, International Psychogeriatrics.

[31]  Joseph K. Pickrell,et al.  DNaseI sensitivity QTLs are a major determinant of human expression variation , 2011, Nature.

[32]  K. Hall,et al.  Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans , 2000, Neurology.

[33]  Maria C. Norton,et al.  Association between APOE ε4 Allele and Vascular Dementia: The Cache County Study , 2010, Dementia and Geriatric Cognitive Disorders.

[34]  R. Corbo,et al.  Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? , 1999, Annals of human genetics.

[35]  R. Stewart,et al.  Apolipoprotein E Genotype, Vascular Risk and Early Cognitive Impairment in an African Caribbean Population , 2001, Dementia and Geriatric Cognitive Disorders.

[36]  Kristopher J Preacher,et al.  Racial Differences in the Influence of the APOE Epsilon 4 Allele on Cognitive Decline in a Sample of Community-Dwelling Older Adults , 2008, Gerontology.

[37]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[38]  Oscar L Lopez,et al.  Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. , 2013, JAMA.

[39]  Scott M. Williams,et al.  The Genetic Structure and History of Africans and African Americans , 2009, Science.

[40]  R. Elston,et al.  A comparative study to screen dementia and APOE genotypes in an ageing East African population , 2010, Neurobiology of Aging.